Factors Influencing the Choice between DOACs and LMWHs

Standard

Factors Influencing the Choice between DOACs and LMWHs : A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism. / Matzdorff, Axel; Langer, Florian.

In: HAMOSTASEOLOGIE, Vol. 40, No. 5, 12.2020, p. 655-661.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{26e9c7b675b44be79347489f87844b11,
title = "Factors Influencing the Choice between DOACs and LMWHs: A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism",
abstract = "Recently direct-acting oral anticoagulants (DOACs) have become a new therapeutic option besides parenteral anticoagulants to treat cancer-associated venous thromboembolism (VTE). With this survey we wanted to identify factors influencing the choice between low-molecular-weight heparin and DOACs among physicians treating cancer patients. A questionnaire was presented at several medical educational activities on cancer care and VTE management between August 2018 and January 2019. One hundred fifteen physicians returned their surveys. The two most compelling arguments pro DOAC were when the patient had no chemotherapy and when he expressed unwillingness to apply injections. The two most important arguments against DOACs were if the patient had problems with taking oral medications or when he had a history of severe bleeding. This survey shows that future studies need to consider many more factors, particularly patient preferences and physician concerns on bleeding risk, to improve their applicability in daily practice.",
author = "Axel Matzdorff and Florian Langer",
note = "Thieme. All rights reserved.",
year = "2020",
month = dec,
doi = "10.1055/a-1129-2573",
language = "English",
volume = "40",
pages = "655--661",
journal = "HAMOSTASEOLOGIE",
issn = "0720-9355",
publisher = "Schattauer",
number = "5",

}

RIS

TY - JOUR

T1 - Factors Influencing the Choice between DOACs and LMWHs

T2 - A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism

AU - Matzdorff, Axel

AU - Langer, Florian

N1 - Thieme. All rights reserved.

PY - 2020/12

Y1 - 2020/12

N2 - Recently direct-acting oral anticoagulants (DOACs) have become a new therapeutic option besides parenteral anticoagulants to treat cancer-associated venous thromboembolism (VTE). With this survey we wanted to identify factors influencing the choice between low-molecular-weight heparin and DOACs among physicians treating cancer patients. A questionnaire was presented at several medical educational activities on cancer care and VTE management between August 2018 and January 2019. One hundred fifteen physicians returned their surveys. The two most compelling arguments pro DOAC were when the patient had no chemotherapy and when he expressed unwillingness to apply injections. The two most important arguments against DOACs were if the patient had problems with taking oral medications or when he had a history of severe bleeding. This survey shows that future studies need to consider many more factors, particularly patient preferences and physician concerns on bleeding risk, to improve their applicability in daily practice.

AB - Recently direct-acting oral anticoagulants (DOACs) have become a new therapeutic option besides parenteral anticoagulants to treat cancer-associated venous thromboembolism (VTE). With this survey we wanted to identify factors influencing the choice between low-molecular-weight heparin and DOACs among physicians treating cancer patients. A questionnaire was presented at several medical educational activities on cancer care and VTE management between August 2018 and January 2019. One hundred fifteen physicians returned their surveys. The two most compelling arguments pro DOAC were when the patient had no chemotherapy and when he expressed unwillingness to apply injections. The two most important arguments against DOACs were if the patient had problems with taking oral medications or when he had a history of severe bleeding. This survey shows that future studies need to consider many more factors, particularly patient preferences and physician concerns on bleeding risk, to improve their applicability in daily practice.

U2 - 10.1055/a-1129-2573

DO - 10.1055/a-1129-2573

M3 - SCORING: Journal article

C2 - 32356293

VL - 40

SP - 655

EP - 661

JO - HAMOSTASEOLOGIE

JF - HAMOSTASEOLOGIE

SN - 0720-9355

IS - 5

ER -